trending Market Intelligence /marketintelligence/en/news-insights/trending/3295c8_keafabycedjxncg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

BioLineRx phase 2 study of cancer treatment meets primary endpoint

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


BioLineRx phase 2 study of cancer treatment meets primary endpoint

BioLineRx Ltd.'s experimental drug BL-8040 was safe and well-tolerated as a single agent for mobilizing hematopoietic stem cells in donors, results from an early stage study showed.

Hematopoietic stem cell mobilization is the process of forcing stem cells, which reside in the bone marrow, into the blood stream.

The study met its primary endpoint, which was the collection of enough stem cell from donors for transplant to recipients.

"Currently, hematopoietic stem cells are mobilized from the bone marrow to the peripheral blood using repeated administrations of G-CSF, followed by leukapheresis [separation of white blood cells], with the whole process lasting almost a week. It is therefore encouraging to see these top-line results, supporting the application of BL-8040 as a single agent for rapid mobilization of hematopoietic stem cells after only one injection," said Geoffrey Uy, from the Division of Oncology at the Washington University School of Medicine, and the principal investigator of the study.